Bicara Therapeutics Reports Positive Early Data for Ficerafusp Alfa Plus Pembrolizumab in Head and Neck Cancer Trial
Reuters
Dec 01, 2025
<a href="https://laohu8.com/S/BCAX">Bicara Therapeutics</a> Reports Positive Early Data for Ficerafusp Alfa Plus Pembrolizumab in Head and Neck Cancer Trial
Bicara Therapeutics Inc. has announced the publication of an abstract with early data from a Phase 1b expansion cohort evaluating 750mg of ficerafusp alfa administered weekly in combination with pembrolizumab in first-line, HPV-negative recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). The results will be highlighted in an oral presentation at the upcoming European Society for Medical Oncology (ESMO) Asia Congress. Preliminary data indicate that the overall response rate and safety profile at the 750mg dose are consistent with those observed at the 1500mg dose. These findings are being used to inform dose selection for the ongoing pivotal FORTIFI-HN01 clinical trial and have supported the FDA Breakthrough Therapy Designation for ficerafusp alfa in this setting. The company will discuss these results in a conference call and webcast scheduled for December 6, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9594082-en) on December 01, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.